Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Active not recruiting 3Withdrawn 2Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 3Classical hematology 2Plasma cell 1

Conditions

Myelodysplastic Syndromes 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia 4Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Lymphoma, Non-Hodgkin 2Immunoproliferative Disorders 2Immune System Diseases 2Cytokine Release Syndrome 2Triple Negative Breast Neoplasms 1Primary Immunodeficiency Diseases 1Osteopetrosis 1Neurotoxicity Syndromes 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1Cytopenia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1

Interventions

fludarabine 6trametinib 5Specimen Handling 5Standard of Care 4Practice Guidelines as Topic 4Magnetic Resonance Spectroscopy 4fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Melphalan 3Interviews as Topic 3GSK2636771 3Cyclophosphamide 3Crizotinib 3Busulfan 3Biopsy 3Antilymphocyte Serum 3AP 1903 reagent 3venetoclax 2thymoglobulin 2palbociclib 2osimertinib 2letermovir 2dabrafenib 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Neoplasms × AP 1903 reagent × Clear all
NCT02477878 2022-07-12

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
10 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03301168 2022-07-12

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Bellicum Pharmaceuticals

Phase 1/2 Active not recruiting
120 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Primary Immunodeficiency Diseases, Cytopenia, Anemia, Aplastic, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Osteopetrosis, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡